



Emend® (fosaprepitant) – First-time generic

- On September 5, 2019, Apotex, Dr. Reddy's, and [Novadoz, the U.S. based affiliate of MSN Labs](#), [launched](#) an [AP-rated](#) generic version of Merck's [Emend \(fosaprepitant\)](#) 150 mg injection.
 - In addition, [Mylan](#), [Lupin](#), [Sungen](#), [Fresenius Kabi](#), [Baxter Healthcare](#), and [Be Pharmaceuticals](#) received FDA approval of their AP-rated generic versions of Emend 150 mg injection. Launch plans are pending for these generics.
 - [Mylan](#) also received FDA approval of generic Emend 115 mg injection. Merck no longer markets this strength of Emend. Launch plans for the generic are pending.
- Emend is approved in combination with other antiemetic agents in adults and pediatric patients 6 months of age and older for the prevention of:
 - Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose [cisplatin](#)
 - Delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
- Emend is also available generically as [aprepitant capsules](#) and as a [brand powder](#) for oral suspension.
 - The capsules carry the same indication as Emend injection but only in patients 12 years and older, and are also approved for the treatment of postoperative nausea and vomiting.
 - The oral suspension carries the same indication as Emend injection.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.